Harmonizing immunophenotyping assay designs facilitates integrating findings across trials, enabling biomarker identification and validation, revealing cohort-specific features and drug mechanisms as ...
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT A multiplex QIF assay was optimized on tissue ...
B-cell maturation antigen (BCMA) is encoded by the TNFRSF17 gene found on the short arm of chromosome 16. BCMA is a type III transmembrane glycoprotein primarily expressed on the surface of myeloma ...
Epstein-Barr virus (EBV) infected and reprogrammed autoreactive B cells in patients with systemic lupus erythematosus (SLE) to become activated antigen-presenting cells. EBV-infected B cells in ...
Adoptive cell therapies, also known as cellular immunotherapies, are a personalized treatment strategy that involves engineering patients’ immune cells to recognize and attack their own tumors. This ...
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback